Clinical Trial Update: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating TUDCA as an add-on treatment for amyotrophic lateral sclerosis (ALS) is in progress, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• TUDCA (Tauroursodeoxycholic acid)

Snippet

Sponsor: Humanitas Mirasole SpA | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Status: UNKNOWN